Ventiv Health to Provide Specialty Oncology Services to MDS Nordion Program to Focus on TheraSphere(R) Product for Primary Hepatocellular Carcinoma SOMERSET, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. (NASDAQ:VTIV) announced today its agreement with MDS Nordion to provide specialty oncology account management representatives to market and sell TheraSphere(R) in the United States. TheraSphere(R) is a technologically advanced form of brachytherapy to treat hepatocellular carcinoma. There are 9,000 cases of this type of liver cancer currently in the U.S. Initially, Ventiv will provide MDS Nordion with two full-time dedicated oncology account specialists who will detail TheraSphere in the U.S. as well as one full-time national business director. Ventiv will recruit, hire and train the TheraSphere team and will develop program procedures, customize processes and establish performance parameters. "TheraSphere offers an alternative to chemotherapy in inoperable cases of primary hepatocellular carcinoma, one of the most common forms of liver cancer in the world," said Peter Pattison, MDS Nordion's VP of Therapeutic Products. "Because of the science and specialization involved in marketing TheraSphere to the physician community, it was important to work with a specialized provider of sales and marketing ideas and solutions. Ventiv is a perfect partner for MDS Nordion in this capacity." Commenting on the agreement, Terrell Herring, President and COO, Ventiv Pharma Services said, "Given Ventiv's flexible structure and specialization in many different areas, we were able to work with MDS Nordion to provide the most comprehensive program for TheraSphere, focusing on oncology and sourcing the best possible sales representatives for this unique therapy." About TheraSphere(R) MDS Nordion's TheraSphere(R), consisting of yttrium-90 (Y-90) glass microspheres, is a technologically advanced form of brachytherapy. TheraSphere(R) is available commercially in the United States as a humanitarian device for use in radiation treatments as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma who can have placement of appropriately positioned hepatic arterial catheters. For more information, please visit http://www.therasphere.com/. About Ventiv Health Ventiv Health, Inc. (NASDAQ:VTIV) is a leading provider of sales, marketing, and compliance solutions to the world's largest pharmaceutical companies as well as to emerging and specialty pharmaceutical and biotech organizations. Ventiv has established its leadership position within the industry based on a long history of building and managing sales teams and providing consultative planning and analytics services across multiple therapeutic areas. The Ventiv delivery model is flexible and client focused, enabling Ventiv to rapidly respond to changing client needs and market conditions across the full spectrum of sales and marketing support, with both integrated and independent programs. These include: Sales and Marketing Teams (Ventiv Sales and Marketing Teams(TM)), Planning and Analytics (Health Products Research(R)), Recruitment (Ventiv Recruitment Services(TM)), Professional Development and Training (Ventiv Professional Development Group(TM)), Marketing Support (PROMOTECH), Data Solutions (Total Data Solutions(TM)), Clinical Support (The Therapeutics Institute(TM)), and Sample Accountability/Patient Assistance Programs (The Franklin Group). Ventiv is a multi-discipline company with a singular focus on providing excellence in customized solutions to meet clients' sales and marketing objectives. Ventiv's approximately 2,600 employees support over forty client organizations. For more information on Ventiv Health, visit http://www.ventiv.com/. About MDS Nordion MDS Nordion, with headquarters in Ottawa, Ontario, is a global leader specializing in radioisotopes, radiation, and related technologies used to diagnose, prevent and treat disease. MDS Nordion is a leader in development and commercialization of radiotherapeutics. In addition to MDS Nordion's proprietary product TheraSphere, MDS Nordion manufactures Bexxar(R) [I-131 tositumomab] for Corixa Corp. and their distributor GlaxoSmithKline, as well as Yttrium-90 Chloride Sterile Solution for use with Zevalin [Y-90 ibritumomab tiuxetan] for Biogen Idec Inc. MDS Nordion (http://www.mds.nordion.com/) is part of MDS Inc., (TSE:MDSTSE:NYSE:TSE:MDZ), an international health and life sciences company based in Canada. In many of its products and services, MDS is among the largest and most respected companies in the world. MDS fights disease. The company's 11,000 employees are working together to advance global health through science, technology and innovation. It does this by providing: laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research services to speed the discovery and development of new drugs, therapy systems for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors. DATASOURCE: Ventiv Health, Inc. CONTACT: John Emery, CFO of Ventiv Health, Inc., +1-732-537-4804, ; or Felicia Vonella of Lazar Partners Ltd., +1-212-867-1762, , for Ventiv Health, Inc. Web site: http://www.ventiv.com/ http://www.mds.nordion.com/ http://www.therasphere.com/

Copyright